What is Artidis?
Artidis operates at the intersection of nanotechnology and clinical oncology, providing a sophisticated platform for rapid tissue analysis. The company's core innovation lies in its ability to integrate nanomechanical biomarkers with traditional clinical data, allowing for the precise evaluation of tumor aggressiveness and the likelihood of metastasis. By offering a more granular understanding of cancer biology, Artidis enables clinicians to move beyond generalized protocols toward highly personalized treatment strategies. This technological edge addresses critical inefficiencies in current diagnostic workflows, positioning the firm as a key player in the precision medicine landscape. The ARTIDISNET platform serves as the backbone of this offering, facilitating data-driven decision-making that directly impacts patient outcomes and therapeutic efficacy.
How much funding has Artidis raised?
Artidis has raised a total of $8.8M across 1 funding round:
Angel/Seed
$8.8M
Angel/Seed (2019): $8.8M with participation from SMD MedicalTrade AG, Zurich, and BERNINA Bioinvest
Key Investors in Artidis
SMD MedicalTrade AG
A specialized investment firm focused on the medical technology sector and healthcare innovation.
Zurich
A prominent Swiss financial institution known for supporting high-growth technology and life science ventures.
BERNINA Bioinvest
A venture capital entity dedicated to funding early-stage biotechnology and medical research initiatives.
What's next for Artidis?
With this major strategic investment, Artidis is poised to expand its clinical footprint and refine its diagnostic capabilities. The focus will likely shift toward scaling the deployment of the ARTIDISNET platform across major healthcare systems, ensuring that its nanomechanical diagnostic tools become a standard component of oncology care. Future growth trajectories will likely involve deepening partnerships with clinical research organizations and expanding the platform's utility to cover a broader spectrum of oncological conditions. As the company matures, the emphasis will remain on validating its diagnostic accuracy through large-scale clinical trials, thereby solidifying its market position as a leader in the next generation of cancer care technology.
See full Artidis company page
